# A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation

> **NCT04473339** · PHASE3 · UNKNOWN · sponsor: **CAI Hongbing** · enrollment: 280 (estimated)

## Conditions studied

- Ovarian Cancer
- Epithelial Ovarian Cancer
- Ovarian Cancer, Epithelial
- Hyperthermic Intraperitoneal Chemotherapy(HIPEC)
- Homologous Recombination Repair Gene Mutation

## Interventions

- **PROCEDURE:** CRS+HIPEC
- **PROCEDURE:** CRS alone

## Key facts

- **NCT ID:** NCT04473339
- **Lead sponsor:** CAI Hongbing
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04473339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04473339, "A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04473339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*